164 related articles for article (PubMed ID: 22086413)
1. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.
Krysov S; Dias S; Paterson A; Mockridge CI; Potter KN; Smith KA; Ashton-Key M; Stevenson FK; Packham G
Blood; 2012 Jan; 119(1):170-9. PubMed ID: 22086413
[TBL] [Abstract][Full Text] [Related]
2. Varicella-zoster virus influences the activities of components and targets of the ERK signalling pathway.
Rahaus M; Desloges N; Wolff MH
J Gen Virol; 2006 Apr; 87(Pt 4):749-758. PubMed ID: 16528022
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
4. IL-4 enhances expression and function of surface IgM in CLL cells.
Aguilar-Hernandez MM; Blunt MD; Dobson R; Yeomans A; Thirdborough S; Larrayoz M; Smith LD; Linley A; Strefford JC; Davies A; Johnson PM; Savelyeva N; Cragg MS; Forconi F; Packham G; Stevenson FK; Steele AJ
Blood; 2016 Jun; 127(24):3015-25. PubMed ID: 27002119
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase: it's been longer than fifteen minutes.
Sturgill TW
Biochem Biophys Res Commun; 2008 Jun; 371(1):1-4. PubMed ID: 18406346
[TBL] [Abstract][Full Text] [Related]
6. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
7. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
8. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
9. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
11. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
12. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
13. Activation of mitogen-activated protein kinases via CD40 is distinct from that stimulated by surface IgM on B cells.
Kashiwada M; Kaneko Y; Yagita H; Okumura K; Takemori T
Eur J Immunol; 1996 Jul; 26(7):1451-8. PubMed ID: 8766546
[TBL] [Abstract][Full Text] [Related]
14. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
15. Activation of
Biran A; Yin S; Kretzmer H; Ten Hacken E; Parvin S; Lucas F; Uduman M; Gutierrez C; Dangle N; Billington L; Regis FF; Rassenti LZ; Mohammad A; Hoffmann GB; Stevenson K; Zheng M; Witten E; Fernandes SM; Tausch E; Sun C; Stilgenbauer S; Brown JR; Kipps TJ; Aster JC; Gnirke A; Neuberg DS; Letai A; Wang L; Carrasco RD; Meissner A; Wu CJ
Cancer Res; 2021 Dec; 81(24):6117-6130. PubMed ID: 34686499
[TBL] [Abstract][Full Text] [Related]
16. Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore.
Drexler HG; Janssen JW; Brenner MK; Hoffbrand AV; Bartram CR
Blood; 1989 May; 73(6):1656-63. PubMed ID: 2496772
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.
Liang Z; Pan Q; Zhang Z; Huang C; Yan Z; Zhang Y; Li J
Mol Med Rep; 2019 Nov; 20(5):4507-4514. PubMed ID: 31702027
[TBL] [Abstract][Full Text] [Related]
18. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
19. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.
Mockridge CI; Potter KN; Wheatley I; Neville LA; Packham G; Stevenson FK
Blood; 2007 May; 109(10):4424-31. PubMed ID: 17255355
[TBL] [Abstract][Full Text] [Related]
20. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways.
de Totero D; Meazza R; Capaia M; Fabbi M; Azzarone B; Balleari E; Gobbi M; Cutrona G; Ferrarini M; Ferrini S
Blood; 2008 Jan; 111(2):517-24. PubMed ID: 17938255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
